BBNX Form 4: CFO Exercises 4,982-Share Option and Executes 10b5-1 Sales
Rhea-AI Filing Summary
Stephen Feider, Chief Financial Officer of Beta Bionics, Inc. (BBNX), reported insider transactions dated 10/03/2025. He acquired 4,982 shares on that date through exercise of an employee stock option with an exercise price of $5.10, bringing his beneficial ownership to 49,023 shares immediately after the acquisition. On the same date he sold 3,828 shares at a weighted average price of $21.5172 and 1,154 shares at a weighted average price of $22.2778, executed pursuant to a Rule 10b5-1 plan adopted on 05/15/2025. After these transactions his reported beneficial ownership is 44,041 shares. The option shares vest in 48 equal monthly installments measured from 09/14/2023.
Positive
- Transaction executed under a Rule 10b5-1 plan (adopted 05/15/2025), providing predetermined, non‑discretionary sale mechanics
- Option exercise increased holdings by 4,982 shares at an exercise price of $5.10, showing use of vested compensation to acquire shares
Negative
- Total beneficial ownership declined from 49,023 shares to 44,041 shares after the sales on 10/03/2025
- CFO sold 4,982 shares in total (3,828 + 1,154), which may reduce insider share concentration
Insights
Concurrent option exercise and planned sales reduced ownership to 44,041 shares.
The CFO exercised an employee stock option to acquire $4,982 shares at an exercise price of $5.10 on 10/03/2025 while selling 3,828 and 1,154 shares at weighted averages of $21.5172 and $22.2778 under a Rule 10b5-1 plan adopted 05/15/2025. The filings show the mechanics: exercise increased holdings before pre‑planned sales reduced them to 44,041.
Dependencies and risks include the fact that sales were executed under a documented plan, which limits interpretive value regarding discretionary insider intent. Monitor quarterly filings and any future Form 4s for material changes in ownership or additional 10b5-1 activity within the next 12 months.
Option vesting schedule and exercise price indicate long‑dated compensation alignment.
The option underlying the acquired shares vests in 48 equal monthly installments measured from 09/14/2023, and the exercise price is $5.10. Post-exercise, the filing reports 69,695 total option shares referenced in Table II prior to the transaction adjustments shown.
Key items to watch: remaining unvested option tranches and future exercises that may dilute equity; review subsequent equity grants disclosed in proxy materials or Form 4s over the next 12 months to assess ongoing compensation dilution.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Employee Stock Option (right to buy) | 4,982 | $0.00 | -- |
| Exercise | Common Stock | 4,982 | $5.10 | $25K |
| Sale | Common Stock | 3,828 | $21.5172 | $82K |
| Sale | Common Stock | 1,154 | $22.2778 | $26K |
Footnotes (1)
- Represents shares sold pursuant to a Rule 10b5-1 Plan adopted on May 15, 2025. The weighted average sale price for the transaction reported was $21.5172 and the range of prices were between $21.04 and $22.0144. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided. The weighted average sale price for the transaction reported was $22.2778 and the range of prices were between $22.0438 and $22..47. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided. The shares subject to this option shall vest in 48 equal monthly installments measured from September 14, 2023.
